• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in

No 04 2024

Malin Otmani

-

November 28, 2024

Share article on X
Share article on Linkedin

Updated: January 31, 2025, 09:21 am

Published: November 28, 2024

Top stories

In a new job – November 18, 2026

Sten Sörensen leaves SynAct Pharma’s board

Sten Sörensen has resigned from the board of SynAct Pharma to focus on his executive responsibilities.

In a new job – November 18, 2026

Cereno Scientific’s chair and a board member step down

Jeppe Øvlesen has resigned as chair and member of the board of Cereno Scientific at his own request, effective immediately, a day after board member Johan Eriksson also left the board.

Pharma Business – November 18, 2026

Biovica wins second pharma work order

Biovica has received a second work order, worth about USD 150,000 (about SEK 1.4 million), from one of the world’s leading pharmaceutical companies under its recently expanded master services agreement.

Biotech Business – November 18, 2026

Lytix Biopharma raises NOK 80 million

Lytix Biopharma has raised NOK 80 million in a private placement and retail offering to prepare a registrational Phase III study of ruxotemitide in neoadjuvant melanoma.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

In a new job - November 18, 2026

Sten Sörensen leaves SynAct Pharma’s board

Sten Sörensen has resigned from the board of SynAct Pharma to focus on his executive responsibilities.

In a new job - November 18, 2026

Cereno Scientific’s chair and a board member step down

Jeppe Øvlesen has resigned as chair and member of the board of Cereno Scientific at his own request, effective immediately, a day after board member Johan Eriksson also left the board.

Pharma Business - November 18, 2026

Biovica wins second pharma work order

Biovica has received a second work order, worth about USD 150,000 (about SEK 1.4 million), from one of the world's leading pharmaceutical companies under its recently expanded master services agreement.

Biotech Business - November 18, 2026

Lytix Biopharma raises NOK 80 million

Lytix Biopharma has raised NOK 80 million in a private placement and retail offering to prepare a registrational Phase III study of ruxotemitide in neoadjuvant melanoma.

Biotech Business - November 18, 2026

Xbrane secures GMP import authorization

Xbrane Biopharma has received authorization from the Swedish Medical Products Agency to import medicinal products from outside the EU/EEA and to certify and release batches for supply within the EU. The approval is expected to simplify the supply chain for its ranibizumab biosimilar Ximluci/Lucamzi, including deliveries of finished product to the US.

Clinical Trials - November 17, 2026

Oncoinvent’s Radspherin clears first randomized safety review

Oncoinvent’s alpha radiopharmaceutical Radspherin has shown no treatment-related serious adverse events in the first interim safety analysis of its ongoing randomized Phase 2 trial in ovarian cancer.

Business article - November 17, 2026

Copenhagen unveils masterplan for innovation district

A new masterplan for Innovation District Copenhagen sets out how up to 300,000 square meters of new floor space for laboratories, offices, and other facilities could be built, with the aim of making the area a world-leading hub for life science and quantum technology.

Sign up to our newsletter: Nordic Life Science News!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.